Modus Therapeutics Holding AB
556851-9523ActiveSwedish biotech developing sevuparin for severe inflammatory conditions.
Oversigt
- 1–4
- Medarbejdere
- 500–749t SEK
- Omsætning
- 2011
- Grundlagt
Nøglebeslutningstagere
John Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
+3 flere kontakter i Funnelfeedr
Beskrivelse
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions. Their primary focus is the development of their proprietary polysaccharide, sevuparin. Sevuparin is being investigated as a potential therapeutic agent for several high unmet m...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Konsultverksamhet avseende företags organisation
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556851952301
Beslutningstagere
7 kontakter i FunnelfeedrJohn Öhd
Chief Executive Officer
Johan Dighed
Board member
Viktor Drvota
Chairman
Michael Forer
Member of the Nomination Committee
Ellen Donnelly
Board Member
Claes Lindblad
CFO & Head of IR
Ellen K. Donnelly
Board Member
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrSangair AB
3 medarbejdereDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
Aptahem AB
0 medarbejdereBiotech company developing RNA therapeutics for acute inflammatory diseases like sepsis.
Kyowa Kirin International NewCo Sweden AB
Global specialty pharmaceutical company focused on innovative drug development.
ZEALAND PHARMA A/S
0 medarbejdereDeveloping peptide medicines for metabolic health challenges globally.
Disruptive Pharma AB (publ)
5–9 medarbejdereSwedish biotech developing novel kidney disease therapies based on proprietary peptides.
Udforsk mere
Spørgsmål om Modus Therapeutics Holding AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo